• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Xa 因子抑制对富含组织因子的表面触发的轴向依赖性动脉血栓形成的影响。

The impact of factor Xa inhibition on axial dependent arterial thrombus formation triggered by a tissue factor rich surface.

机构信息

Department of Biochemistry, University of Cambridge, Cambridge CB1 2QW, UK.

出版信息

J Thromb Thrombolysis. 2012 Jan;33(1):6-15. doi: 10.1007/s11239-011-0658-6.

DOI:10.1007/s11239-011-0658-6
PMID:22120925
Abstract

This study was designed to assess the effect of Factor Xa antagonists on thrombus formation at various axial positions on a tissue factor rich surface under arterial blood flow conditions. Non-anticoagulated, flowing human blood, drawn directly from an antecubital vein, was perfused over a tissue factor coated cover slip in a parallel-plate perfusion chamber. Thrombus surface coverage, thrombus mean height and fibrin surface coverage were measured at six different axial positions by confocal microscopy. Both thrombus surface coverage and mean height decreased along the cover slip axis whereas the fibrin surface coverage increased. Pre-chamber treatment of blood with the direct Factor Xa inhibitors Razaxaban and 813893 resulted in significantly reduced thrombus and fibrin formation at all axial positions investigated (P < 0.05). Thrombus and fibrin deposition in a laminar flow chamber changed with axial position with surface coverage measurements being more reproducible than thrombus mean height. Data were more reproducible towards the centre of the flow chamber than at the extremities. Razaxaban and 813893 inhibited thrombus and fibrin formation at the highest concentrations tested. No difference in drug effect was apparent at different axial positions. In conclusion, axial position influences the degree of thrombus and fibrin deposition with measurements being less reproducible at the extremities of the flow chamber. This technique may prove useful for analysing anti-thrombotic drug effects before progression to clinical trials.

摘要

本研究旨在评估 Xa 因子拮抗剂在富含组织因子的表面上在动脉血流条件下的不同轴向位置形成血栓的效果。非抗凝、从肘前静脉直接抽取的流动人体血液在平行板灌注室中的组织因子涂层盖玻片上进行灌注。通过共焦显微镜测量血栓表面覆盖率、血栓平均高度和纤维蛋白表面覆盖率在六个不同轴向位置。血栓表面覆盖率和平均高度沿着盖玻片轴下降,而纤维蛋白表面覆盖率增加。在预腔室中用直接 Xa 因子抑制剂 Razaxaban 和 813893 处理血液,导致在所有研究的轴向位置上血栓和纤维蛋白形成显著减少(P < 0.05)。层流室中的血栓和纤维蛋白沉积随轴向位置而变化,表面覆盖率测量比血栓平均高度更具可重复性。数据在流室中心比在末端更具可重复性。Razaxaban 和 813893 在测试的最高浓度下抑制血栓和纤维蛋白形成。在不同的轴向位置上,药物效应没有明显差异。总之,轴向位置影响血栓和纤维蛋白沉积的程度,在流室的末端测量的可重复性较低。该技术在进展到临床试验之前可能有助于分析抗血栓药物的效果。

相似文献

1
The impact of factor Xa inhibition on axial dependent arterial thrombus formation triggered by a tissue factor rich surface.Xa 因子抑制对富含组织因子的表面触发的轴向依赖性动脉血栓形成的影响。
J Thromb Thrombolysis. 2012 Jan;33(1):6-15. doi: 10.1007/s11239-011-0658-6.
2
Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis.在剪切力依赖性人血栓形成的体外模型中,选择性抑制因子Xa对组织因子/因子VIIa或胶原引发的动脉血栓形成的影响。
Arterioscler Thromb Vasc Biol. 1995 Dec;15(12):2188-94. doi: 10.1161/01.atv.15.12.2188.
3
Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model.在流动和静态条件下直接凝血酶抑制剂与因子Xa抑制剂联合抗血小板药物的比较评估:体外流动腔模型
PLoS One. 2014 Jan 31;9(1):e86491. doi: 10.1371/journal.pone.0086491. eCollection 2014.
4
Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.利伐沙班,一种直接的Xa因子抑制剂,与阿司匹林和/或氯吡格雷联合使用可提高低剂量抗血栓活性,且不会增加家兔的出血风险。
J Thromb Thrombolysis. 2007 Aug;24(1):43-51. doi: 10.1007/s11239-007-0017-9. Epub 2007 Feb 24.
5
Tissue factor-induced coagulation triggers platelet thrombus formation as efficiently as fibrillar collagen at arterial blood flow conditions.在动脉血流条件下,组织因子诱导的凝血与纤维状胶原蛋白一样有效地触发血小板血栓形成。
Arterioscler Thromb. 1994 Dec;14(12):1976-83. doi: 10.1161/01.atv.14.12.1976.
6
Effects of ionic and nonionic contrast media on endothelium and on arterial thrombus formation.离子型和非离子型造影剂对内皮及动脉血栓形成的影响。
Acta Radiol. 1996 Nov;37(6):954-61. doi: 10.1177/02841851960373P2102.
7
Platelet deposition inhibits tissue factor activity: in vitro clots are impermeable to factor Xa.血小板沉积会抑制组织因子活性:体外凝块对Xa因子具有不透性。
Blood. 2004 Jul 1;104(1):123-7. doi: 10.1182/blood-2003-12-4352. Epub 2004 Mar 11.
8
Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.给予冠状动脉疾病患者 ZK-807834 直接抑制因子 Xa 具有强大的动脉抗血栓作用。
Thromb Haemost. 2007 Mar;97(3):487-92.
9
Functional characterization of tissue factor in von Willebrand factor-dependent thrombus formation under whole blood flow conditions.全血流条件下组织因子在血管性血友病因子依赖性血栓形成中的功能特性
Int J Hematol. 2016 Dec;104(6):661-668. doi: 10.1007/s12185-016-2086-z. Epub 2016 Aug 25.
10
Retinoic acid reduces induction of monocyte tissue factor and tissue factor/factor VIIa-dependent arterial thrombus formation.视黄酸可减少单核细胞组织因子的诱导以及组织因子/因子VIIa依赖性动脉血栓形成。
Blood. 1995 Jul 1;86(1):212-8.

引用本文的文献

1
Whole Blood Based Multiparameter Assessment of Thrombus Formation in Standard Microfluidic Devices to Proxy In Vivo Haemostasis and Thrombosis.基于全血的标准微流控装置中血栓形成的多参数评估以模拟体内止血和血栓形成
Micromachines (Basel). 2019 Nov 16;10(11):787. doi: 10.3390/mi10110787.

本文引用的文献

1
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.利伐沙班的发现与开发,一种口服、直接的 Xa 因子抑制剂。
Nat Rev Drug Discov. 2011 Jan;10(1):61-75. doi: 10.1038/nrd3185. Epub 2010 Dec 17.
2
New oral anticoagulant drugs in cardiovascular disease.新型口服抗凝药物在心血管疾病中的应用。
Thromb Haemost. 2010 Jul;104(1):49-60. doi: 10.1160/TH09-05-0327. Epub 2010 Jun 10.
3
Synergism between platelet collagen receptors defined using receptor-specific collagen-mimetic peptide substrata in flowing blood.
在流动的血液中使用受体特异性胶原蛋白模拟肽底物定义血小板胶原受体之间的协同作用。
Blood. 2010 Jun 17;115(24):5069-79. doi: 10.1182/blood-2010-01-260778. Epub 2010 Mar 29.
4
A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques.人动脉粥样硬化斑块诱导动脉血栓形成的两步机制。
J Am Coll Cardiol. 2010 Mar 16;55(11):1147-58. doi: 10.1016/j.jacc.2009.11.051.
5
Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.GW813893的抗血栓形成潜力:一种新型的、口服活性的、作用于活性位点的Xa因子抑制剂。
J Cardiovasc Pharmacol. 2008 Jul;52(1):66-71. doi: 10.1097/FJC.0b013e31817e9b9e.
6
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.抗凝治疗的现状与未来展望:Xa因子和IIa因子抑制剂
Semin Thromb Hemost. 2008 Feb;34(1):39-57. doi: 10.1055/s-2008-1066023.
7
Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber.DU-176b抑制因子Xa的抗血栓形成作用:一项使用体外流动腔的口服直接因子Xa抑制剂的I期研究。
Thromb Haemost. 2007 Oct;98(4):883-8. doi: 10.1160/th07-04-0312.
8
Selective and dual action orally active inhibitors of thrombin and factor Xa.凝血酶和Xa因子的选择性及双重作用口服活性抑制剂。
Bioorg Med Chem Lett. 2007 May 15;17(10):2927-30. doi: 10.1016/j.bmcl.2007.03.080. Epub 2007 Mar 30.
9
Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.正在研发用于预防和治疗血栓栓塞性疾病的口服直接凝血因子Xa抑制剂。
Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1238-47. doi: 10.1161/ATVBAHA.107.139402. Epub 2007 Mar 22.
10
Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.给予冠状动脉疾病患者 ZK-807834 直接抑制因子 Xa 具有强大的动脉抗血栓作用。
Thromb Haemost. 2007 Mar;97(3):487-92.